YD Bio Ltd
ir.ydesgroup.comWhat Do They Do?
Provides cancer diagnostic testing and clinical supply services, and sells healthcare and eye-care products to pharmaceutical and biotechnology companies, licensed health professionals, and retail customers.
20-F for FY2025, filed Apr 30, 2026
How Do They Make Money?
Revenue comes from product sales to corporate and retail customers. Customers pick up goods at the company's premises and sign an acceptance document when they take delivery.
20-F for FY2025, filed Apr 30, 2026The Company’s revenue from contracts with customers is derived from product revenue principally from the sales of products directly to its…View ↗
The performance obligations are considered to be met, and revenue is recognized when the customer obtains control of the goods. Revenue is…View ↗
For the years ended December 31, 2025, 2024 and 2023, the Company’s revenue was all recognized at point of time.View ↗
-
20-F for FY2025, filed Apr 30, 2026
FY2025 revenue by product or service ↗
$596.8K
-
20-F for FY2025, filed Apr 30, 2026
$596.8K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Medical and related products
Sold outright
20-F for FY2025, filed Apr 30, 2026 |
47% |
Medical and related products, FY2025
$280.8K Sources
|
Sold outright |
|
Drugs
Sold outright
20-F for FY2025, filed Apr 30, 2026 |
37% |
Drugs, FY2025
$223.4K Sources
|
Sold outright |
|
Beauty products
Sold outright
|
8.4% |
Beauty products, FY2025
$49.9K Sources
|
Sold outright |
|
Contact lenses
Sold outright
|
5.9% |
Contact lenses, FY2025
$35K Sources
|
Sold outright |
|
Nutritional products
Sold outright
|
0.9% |
Nutritional products, FY2025
$5.2K Sources
|
Sold outright |
|
Supplements
Sold outright
|
0.4% |
Supplements, FY2025
$2.5K Sources
|
Sold outright |
Who Are Their Customers?
Corporate and retail customers, primarily in Taiwan, buy directly; customers pick up goods at the company's premises.
20-F for FY2025, filed Apr 30, 2026The Company’s customers primarily consist of corporate and retail customers in Taiwan. For the year ended December 31, 2025, the Company’s…View ↗
The Company’s revenue from contracts with customers is derived from product revenue principally from the sales of products directly to its…View ↗
The performance obligations are considered to be met, and revenue is recognized when the customer obtains control of the goods. Revenue is…View ↗
Do Revenues Turn Into Profits?
No. It lost $8.3M in FY2025.
20-F for FY2025, filed Apr 30, 2026
−$5.3MView ↗
20-F for FY2025, filed Apr 30, 2026
−$8.3MView ↗
20-F for FY2025, filed Apr 30, 2026
−$8MView ↗
How Are They Changing?
Who Do They Compete With?
Competes with ArcherDx, Burning Rock Biotech, Exact Sciences, Freenome, Guardant Health, Laboratory for Advanced Medicine, Singlera Genomics, Thrive Earlier Detection, GRAIL, Breakthrough Genomics, Roche Diagnostics, Johnson & Johnson, Alcon, Regeneron Pharmaceuticals, Aegle Therapeutics, ArunA Biomedical, Capricor Therapeutics, and ReNeuron Group
20-F for FY2025, filed Apr 30, 2026There are several companies, such as ArcherDx, Inc. (AnchorDx), Burning Rock Biotech Limited, Exact Sciences Corporation, Freenome Inc.…View ↗
Loading...
